🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Baxter International Inc. BAX SPX

Healthcare · Medical Instruments & Supplies · United States
https://www.baxter.com
Company Profile ↓
$22.15
-21.70% 1Y
Mkt Cap$11.44B
P/E-11.60
P/B1.86
Div. Yield0.89%
52W High$28.97
52W Low$15.79
Book Value$11.70
EPS (TTM)$-1.91

Company Overview

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $11.24B (+5.7% YoY); net profit $-957.00M.
  • Trailing 12 Months Year-on-year growth — revenue +2.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.01%
1 Year:2.90%

Stock Price Performance

1 Year:-21.70%
6 Months:+10.04%
3 Months:+25.99%
1 Month:+6.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 48% of range
$15.79 $28.97
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross3d ago
  • RSI (14)58.17 · Neutral
Price Performance
1M+6.18%
3M+25.99%
6M+10.04%
1Y-21.70%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-11.60
Industry PE
25.88
Forward P/E
11.02
PEG Ratio
36.68
Book Value
$11.70
Price to Book
1.86
P/S
0.99
EV/EBITDA
9.90
Dividend Yield
0.89%

Growth (CAGR)

Revenue 5Y
-0.01%
Profit 5Y
-
Revenue (YoY)
2.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
1.04%
ROE
-15.01%
ROA
2.85%
Profit Margin
-9.70%
Op Margin
6.03%
Gross Margin
34.65%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-1.91

Balance Sheet & Liquidity

Debt/Equity
1.61
Quick Ratio
1.02
Current Ratio
1.85
Debt
$9.69B
Total Assets
$19.85B
Current Assets
$6.85B
Working Capital
$3.90B

Ownership

Promoter Holding
0.34%
Chg in Prom Hold
-
FII / Inst Holding
106.11%
Chg in FII Hold
-0.13%

Financial Snapshot

Enterprise Value
$11.44B
Total Revenue (TTM)
$11.32B
EBITDA
$1.91B
Free Cash Flow
$900.88M
Operating Cash Flow
$1.25B
Shares Outstanding
516.47M
Gross Margin
34.65%
Payout Ratio
307.69%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BAX Baxter International Inc. SPX 22.15 -11.60 $11.44B 0.89% 1.04% -15.01% -0.01% -
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ----2.48B2.60B2.71B2.77B2.69B2.81B2.76B2.83B2.64B2.83B2.85B3.04B2.80B2.72B2.97B3.18B2.95B3.10B3.23B3.56B3.59B3.61B3.75B2.44B2.59B2.60B2.73B2.49B2.69B--2.62B2.81B2.83B2.97B2.70B
Cost of Revenue -----------------------------------1.76B1.82B1.89B2.40B1.81B
Gross Profit 965.00M972.00M1.07B1.10B1.04B1.13B1.13B1.16B1.12B1.22B1.23B1.18B1.08B1.15B1.23B1.30B1.16B1.04B1.20B1.19B1.15B1.23B1.32B1.26B1.37B1.04B1.39B964.00M1.03B1.06B1.10B961.00M1.03B--861.00M991.00M950.00M577.00M891.00M
Operating Expenses -----------------------------------803.00M800.00M778.00M821.00M825.00M
Operating Income 188.00M68.00M186.00M-353.00M347.00M300.00M-434.00M377.00M382.00M391.00M383.00M350.00M503.00M-409.00M331.00M470.00M-390.00M424.00M513.00M163.00M264.00M-2.88B-129.00M-17.00M179.00M-115.00M179.00M--58.00M191.00M172.00M-244.00M66.00M
EBITDA -----------------------------------325.00M462.00M426.00M-447.00M309.00M
Interest Expense -----------------------------------81.00M72.00M68.00M69.00M78.00M
Pretax Income ------------------------------------3.00M133.00M121.00M-756.00M-6.00M
Tax Provision ------------------------------------67.00M11.00M172.00M279.00M11.00M
Net Income 3.38B1.21B130.00M243.00M272.00M265.00M251.00M-71.00M382.00M341.00M518.00M305.00M342.00M313.00M369.00M-23.00M332.00M246.00M356.00M168.00M298.00M298.00M450.00M71.00M252.00M-2.94B181.00M44.00M-141.00M2.51B245.00M37.00M-314.00M--126.00M91.00M-46.00M-1.13B-15.00M
Diluted EPS 6.122.190.240.440.490.480.45-0.130.690.620.950.570.660.600.71-0.050.640.480.690.330.580.590.890.140.50-5.830.360.09-0.284.930.480.07-0.61---0.030.18-0.09-2.19-0.03
R&D Expense 136.00M195.00M159.00M-127.00M155.00M150.00M-141.00M172.00M166.00M175.00M129.00M166.00M144.00M-146.00M117.00M123.00M-128.00M139.00M129.00M150.00M148.00M151.00M-164.00M165.00M133.00M-120.00M130.00M129.00M-140.00M134.00M118.00M-139.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 11.26B12.35B12.56B12.84B13.89B13.94B9.41B10.72B9.97B10.16B10.58B11.10B11.36B11.67B-10.06B10.36B10.64B11.24B
Cost of Revenue ---------------6.51B6.21B6.65B7.87B
Gross Profit 5.52B6.13B6.53B5.96B7.05B7.13B4.16B4.58B4.15B4.12B4.47B4.76B4.76B4.59B-3.55B4.15B3.98B3.38B
Operating Expenses ---------------3.58B3.44B3.54B3.20B
Operating Income ------496.00M656.00M449.00M745.00M1.29B1.58B1.77B1.62B--33.00M707.00M439.00M177.00M
EBITDA ----------------1.76B1.73B1.12B766.00M
Interest Expense ---------------413.00M508.00M408.00M290.00M
Pretax Income ----------------3.25B242.00M-289.00M-505.00M
Tax Provision ----------------135.00M61.00M37.00M395.00M
Net Income 1.71B2.01B2.21B1.42B2.22B2.33B2.01B2.50B968.00M4.96B602.00M1.55B1.00B1.10B--2.43B2.66B-649.00M-957.00M
Diluted EPS 2.613.163.592.393.884.183.664.561.769.011.082.831.932.13--4.835.25-1.27-1.87
R&D Expense 760.00M868.00M917.00M915.00M946.00M1.08B582.00M610.00M603.00M646.00M615.00M654.00M595.00M521.00M531.00M450.00M518.00M590.00M518.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --15.40B17.35B17.49B19.07B20.39B25.22B26.14B20.96B15.55B17.11B-16.84B16.52B16.80B15.72B16.24B17.50B18.19B20.02B-28.29B28.28B25.78B20.05B
Current Assets ----------------------8.01B9.60B8.85B6.87B
Cash & Equivalents 2.48B2.54B2.13B2.79B2.69B2.90B3.27B2.73B2.92B2.21B2.80B3.39B-2.95B2.86B2.86B1.84B1.90B2.93B3.33B3.73B-1.72B3.08B1.76B1.97B
Inventory ----------------------2.68B1.92B2.05B2.23B
Receivables ----------------------2.57B1.72B1.68B1.86B
Total Liabilities -----------8.00B-7.78B7.69B7.71B7.85B8.65B9.70B10.28B11.29B-22.39B19.81B18.76B13.95B
Current Liabilities --3.63B4.46B4.04B4.86B4.76B5.25B6.04B5.75B2.74B2.82B-2.60B2.59B2.66B2.81B3.28B2.56B3.23B3.33B-4.75B6.50B6.51B2.97B
Long Term Debt --------------------6.23B-15.23B11.09B10.37B9.47B
Total Debt ----------------------17.20B14.11B13.45B9.78B
Total Equity -7.01B6.23B7.19B6.57B6.58B6.94B8.46B8.12B8.85B8.29B9.12B-161.00M9.07B8.84B9.11B7.84B7.57B7.78B7.88B8.69B-5.83B8.40B6.96B6.13B
Shares Outstanding ----------------------683.49M683.49M683.49M683.49M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 2.31B2.52B2.91B3.00B2.82B3.11B3.20B3.21B1.77B1.65B1.71B2.02B2.10B1.87B-1.21B1.73B1.02B845.00M
Investing Cash Flow -305.00M-993.00M-1.15B-1.26B-1.43B-1.57B-5.36B-1.54B-1.81B-715.00M-1.29B-916.00M-1.10B-1.18B--931.00M3.21B-626.00M2.84B
Financing Cash Flow -1.97B-1.93B-1.01B-1.72B-1.14B-1.11B1.65B-1.40B-481.00M-324.00M93.00M-2.60B498.00M-345.00M--1.44B-3.49B-1.08B-4.22B
Capital Expenditure ----------------635.00M-436.00M-460.00M-522.00M
Free Cash Flow ---------------576.00M1.29B559.00M323.00M
Net Change in Cash ----------------1.16B1.45B-688.00M-530.00M
Share Buybacks 1.85B1.99B1.22B1.45B1.58B1.48B913.00M550.00M-292.00M564.00M2.45B1.27B500.00M600.00M32.00M00-

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 49.0%49.6%51.9%46.4%50.7%51.2%44.2%42.7%41.6%40.5%42.3%42.9%41.9%39.3%-35.3%40.1%37.5%30.1%
Operating Margin % ------5.3%6.1%4.5%7.3%12.2%14.3%15.6%13.8%--0.3%6.8%4.1%1.6%
Net Margin % 15.2%16.3%17.6%11.1%16.0%16.7%21.4%23.3%9.7%48.9%5.7%13.9%8.8%9.4%--24.2%25.6%-6.1%-8.5%
ROE % 24.4%32.3%30.7%21.6%33.8%33.5%23.8%30.8%10.9%59.9%6.6%19.7%12.7%12.7%--41.7%31.6%-9.3%-15.6%
ROCE % ------2.5%3.3%3.0%5.8%9.0%12.3%11.8%9.7%--0.1%3.2%2.3%1.0%

Shareholding Pattern

Insiders
0.34%
Institutions
106.11%
Public Float
106.47%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.37% 79.40M $1.73B
2 Pzena Investment Management LLC 12.49% 64.53M $1.41B
3 Dodge & Cox Inc. 11.09% 57.25M $1.25B
4 FMR, LLC 8.96% 46.26M $1.01B
5 Vanguard Capital Management LLC 6.49% 33.51M $730.45M
6 Vanguard Portfolio Management LLC 4.65% 23.99M $523.06M
7 State Street Corporation 3.87% 19.98M $435.56M
8 Greenhaven Associates, Inc. 2.77% 14.31M $311.91M
9 Geode Capital Management, LLC 2.66% 13.76M $300.03M
10 Invesco Ltd. 2.54% 13.12M $286.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BAX

Yahoo Finance Wed, 15 Jul 2026

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income fr…

Yahoo Finance Wed, 15 Jul 2026

3 Cash-Producing Stocks with Warning Signs

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Yahoo Finance hu, 09 Jul 2026

Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill., July 09, 2026--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. …

Yahoo Finance hu, 09 Jul 2026

Retia Medical Appoints Christopher Benassi to Strategic Advisory Board

Retia Medical, the developer of cardiovascular intelligence software that transforms routine physiologic monitoring data into actionable clinical insight, today announced the appointment of Christopher Benassi, former Vice President, Connec…

Yahoo Finance hu, 09 Jul 2026

3 Healthcare Stocks We Think Twice About

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 10% over the past six months, topping the S&P 500 …

Yahoo Finance Wed, 08 Jul 2026

Baxter International's Q2 2026 Earnings: What to Expect

Baxter International will release its second-quarter earnings soon, and analysts anticipate a double-digit profit dip.

BAX — Frequently Asked Questions

What is the current share price of Baxter International Inc. (BAX)?

As of 2026-07-15 16:51 PDT, Baxter International Inc. (BAX) trades at $22.15 on NYSE. Its 52-week range is $15.79 to $28.97.

What is the market capitalisation of BAX?

Baxter International Inc. (BAX) has a market capitalisation of $11.44B on NYSE.

What is the P/E ratio of BAX?

BAX trades at a trailing price-to-earnings (P/E) ratio of -11.60. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.86.

Does BAX pay a dividend?

Baxter International Inc. (BAX) currently offers a dividend yield of 0.89%.

What is the return on equity (ROE) of BAX?

BAX has a return on equity (ROE) of -15.01%. Its return on capital employed (ROCE) is 1.04%.

Is BAX a good stock to buy?

This page provides a data-driven analysis of Baxter International Inc. (BAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space